Skip to main content

Akero Therapeutics, Inc.

AKRODelisted Dec 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001744659

Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Akero Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of AKRO: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders10997−12
Shares31.5M27.7M−3.76M (−11.9%)
Value$913.6M$684.2M−$229.4M (−25.1%)

New holders (7)

Institutions that held Akero Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to AKRO in Q2 2021
InstitutionSharesValue% of portfolio
Bridgefront Capital, LLC12,099$300.0K0.11%
State Board of Administration of Florida Retirement System11,915$296.0K0.00%
Voya Investment Management LLC10,067$250.0K0.00%
Invesco Ltd.10,029$249.0K0.00%
Cubist Systematic Strategies, LLC9,613$238.0K0.00%
Nan Fung Group Holdings Ltd3,470$86.0K0.03%
Geneos Wealth Management Inc.50$1.00K0.00%

Sold out (19)

Institutions that held Akero Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.